Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors

Circulation

Volumn 93, Issue 2, 1996, Pages 301-309

  Dichek, David A ^b   Anderson, Johanna ^a   Kelly, Andrew B ^a   Hanson, Stephen R ^a   Harker, Laurence A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

endothelium; plasminogen activators; thrombosis

Indexed keywords

BETA THROMBOGLOBULIN; FIBRINOGEN; FIBRINOPEPTIDE A; INDIUM 111; IODINE 125; RECOMBINANT PLASMINOGEN ACTIVATOR; THROMBOCYTE FACTOR 4; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BABOON; BLOOD CLOT LYSIS; BLOOD VESSEL GRAFT; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBRINOLYSIS; GENE TRANSFER; GENETIC TRANSDUCTION; HEMOSTASIS; MALE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 0030054260     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.2.301     Document Type: Article

References (49)

1. Harker LA, Mann KG. Thrombosis and fibrinolysis. In: Fuster V, Verstraete M, eds. Thrombosis in Cardiovascular Disorders. Philadelphia, Pa: WB Saunders Co; 1992:1-16.
2. Esmon CT. The regulation of natural anticoagulant pathways. Science. 1987;235:1348-1352.
3. Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest. 1993;92:2003-2012.
4. Weksler BB, Marcus AJ, Jaffe EA. Synthesis of prostaglandin 1-2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci U S A. 1977;74:3922-3926.
5. Moncada S. Prostacyclin and arterial wall biology. Arteriosclerosis. 1982;2:193-207.
6. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987;84: 9265-9269.
7. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-526.
8. De Graaf JC, Banga JD, Moncada S, Palmer RMJ, de Groot PG, Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation. 1992;85:2284-2290.
9. Levin EG. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci U S A. 1983;80:6804-6808.
10. Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV. Cloning and expression of human tissue-type plasminogen activator cDNA in E coli. Nature. 1983;301:214-221.
11. Dichek D, Quertermous T. Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Blood. 1989;74:222-228.
12. Zwiebel JA, Freeman SM, Kantoff PW, Cornetta K, Ryan US, Anderson WF. High-level recombinant gene expression in rabbit endothelial cells transduced by retroviral vectors. Science. 1989;243: 220-222.
13. Dichek DA, Neville RF, Zwiebel JA, Freeman SM, Leon MB, Anderson WF. Seeding of intravascular stents with genetically engineered endothelial cells. Circulation. 1989;80:1347-1353.
14. Nabel EG, Plautz G, Boyce FM, Stanley JC, Nabel GJ. Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science. 1989;244:1342-1344.
15. Conte MS, Birinyi LK, Miyata T, Fallon JT, Gold HK, Whittemore AD, Mulligan RC. Efficient repopulation of denuded rabbit arteries with autologous genetically modified endothelial cells. Circulation. 1994;89:2161-2169.
16. Flugelman MY, Virmani R, Leon MB, Bowman RL, Dichek DA. Genetically engineered endothelial cells remain adherent and viable after stent deployment and exposure to flow in vitro. Circ Res. 1992;70:348-354.
17. Shayani V, Newman KD, Dichek DA. Optimization of recombinant t-PA secretion from seeded vascular grafts. J Surg Res. 1994;57: 495-504.
18. Wilson JM, Birinyi LK, Salomon RN, Libby P, Callow AD, Mulligan RC. Implantation of vascular grafts lined with genetically modified endothelial cells. Science. 1989;244:1344-1346.
19. Dichek DA, Nussbaum O, Degen SJF, Anderson WF. Enhancement of the fibrinolytic activity of sheep endothelial cells by retroviral vector-mediated gene transfer. Blood. 1991;77:533-541.
20. Lee SW, Kahn ML, Dichek DA. Expression of an anchored urokinase in the apical endothelial cell membrane. J Biol Chem. 1992;267:13020-13027.
21. Lee SW, Ellis V, Dichek DA. Characterization of plasminogen activation by glycosylphosphatidylinositol-anchored urokinase. J Biol Chem. 1994;269:2411-2418.
22. Dichek DA, Lee SW, Nguyen NH. Characterization of recombinant plasminogen activator production by primate endothelial cells transduced with retroviral vectors. Blood. 1994;84:504-516.
23. Lisanti MP, Rodriguez-Boulan E. Polarized sorting of GPI-linked proteins in epithelia and membrane microdomains. Cell Biol Int. 1991;15:1023-1049.
24. Schneider PA, Hanson SR, Price TM, Harker LA. Confluent durable endothelialization of endarterectomized baboon aorta by early attachment of cultured endothelial cells. J Vasc Surg. 1990;11:365-372.
25. Schneider PA, Hanson SR, Price TM, Harker LA. Durability of confluent endothelial cell monolayers on small-caliber vascular prostheses in vitro. Surgery. 1988;103:456-462.
26. Hanson SR, Kotze HF, Savage B, Harker LA. Platelet interactions with Dacron vascular grafts: a model of acute thrombosis in baboons. Arteriosclerosis. 1985;5:595-603.
27. Runge MS, Harker LA, Bode C, Ruef J, Kelly AB, Marzec UM, Caban R, Shaw S-Y, Haber E, Hanson SR. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. Circulation. In press.
28. 111Indium-labeled platelets in baboons. Blood. 1986;68:386-393.
29. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
30. Harker LA, Hanson SR, Kirkman TR. Experimental arterial thromboembolism in baboons: mechanism, quantitation, and pharmacologic prevention. J Clin Invest. 1979;64:559-569.
31. Cadroy Y, Harker LA, Hanson SR. Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): comparison with standard heparin. J Lab Clin Med. 1989;114:349-357.
32. Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethylketone. Proc Natl Acad Sci U S A. 1988;85: 3184-3188.
33. Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood. 1991;77:1006-1012.
34. Sherry S. Fibrinolysis, Thrombolysis and Hemostasis: Concepts, Perspectives, and Clinical Applications. Malvern, Pa: Lea & Febiger; 1992:18-23.
35. Gimbrone MA Jr. Vascular endothelium: nature's blood container. In: Gimbrone MA Jr, ed. Vascular Endothelium in Hemostasis and Thrombosis. New York, NY: Churchill Livingstone; 1986:1-13.
36. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 1994;368:419-424.
37. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
38. Lumsden AB, Kelly AB, Schneider PA, Krupski WC, Dodson T, Hanson SR, Harker LA. Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2Cl in baboons. Blood. 1993;81:1762-1770.
39. Nemerson Y, Turitto VT. The effect of flow on hemostasis and thrombosis. Thromb Haemost. 1991;66:272-276.
40. Bu G, Warshawsky I, Schwartz AL. Cellular receptors for the plasminogen activators. Blood. 1994;83:3427-3436.
41. Madison EL, Goldsmith EJ, Gerard RD, Gething MJ, Sambrook JF. Serpin-resistant mutants of human tissue-type plasminogen activator. Nature. 1989;339:721-724.
42. Madison EL, Goldsmith EJ, Gerard RD, Gething MH, Sambrook JF, Bassel-Duby RS. Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. Proc Natl Acad Sci U S A. 1990;87:3530-3533.
43. van Mourik JA, Lawrence DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem. 1984;259:14914-14921.
44. Li X-K, Lijnen HR, Nelles L, Van Hoef B, Stassen JM, Collen D. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1. Blood. 1992; 79:417-429.
45. Hanson SR, Harker LA. Baboon models of acute arterial thrombosis. Thromb Haemost. 1987;58:801-805.
46. Del Zoppo GJ, Copeland BR, Harker LA, Waltz TA, Zyroff J, Hanson SR, Battenberg E. Experimental acute thrombotic stroke in baboons. Stroke. 1986;17:1254-1265.
47. Fischlein T, Zilla P, Meinhart J, Puschmann R, Vesely M, Eberl T, Balon R, Deutsch M. In vitro endothelialization of a mesosystemic shunt: a clinical case report. J Vasc Surg. 1994;19:549-554.
48. Zilla P, Deutsch M, Meinhart J, Puschmann R, Eberl T, Minar E, Dudezak R, Lugmaier H, Schmidt P, Noszian I, Fischlein T. Clinical in vitro endothelialization of femoropopliteal bypass grafts: an actuarial follow-up over three years. J Vasc Surg. 1994;19: 540-548.
49. Schneider P, Hanson S, Price T, Harker L. Preformed confluent endothelial cell monolayers prevent early platelet deposition on vascular prostheses in baboons. J Vasc Surg. 1988;8:2229-2235.